Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Inmune Bio, retaining the price target of $8.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jason McCarthy has given his Buy rating due to a combination of factors, primarily focusing on the promising aspects of Inmune Bio’s pipeline despite the recent challenges. The company’s Phase 2 MINDFuL study of XPro, although not meeting its primary endpoint, showed positive trends in a specific Alzheimer’s subgroup with high neuroinflammation, demonstrating potential efficacy and a strong safety profile without amyloid-related side effects. This positions Inmune Bio well for future discussions with the FDA and potential partnerships to advance the program.
Moreover, McCarthy highlights the broader potential within Inmune Bio’s pipeline, including INKmune for prostate cancer and CORDstom for recessive epidermolysis bullosa (RDEB), which could leverage the growing interest in stem cell therapies. The recent approval of similar therapies by other companies suggests a favorable regulatory environment, which could benefit Inmune Bio’s ongoing and future developments. As these programs progress, there is an expectation that the company’s stock could recover and gain value, supporting the Buy recommendation.